Ascelia Pharma AB (OSTO:ACE) Stock Based Compensation : kr-0.16 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB Stock Based Compensation?

Ascelia Pharma AB's Stock Based Compensation for the three months ended in Mar. 2025 was kr0.52 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was kr-0.16 Mil.

Ascelia Pharma AB Stock Based Compensation Historical Data

The historical data trend for Ascelia Pharma AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Stock Based Compensation Chart

Ascelia Pharma AB Annual Data

Trend

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

7.87

5.92

1.63

2.93

4.34

Ascelia Pharma AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Stock Based Compensation	Get a 7-Day Free Trial															5.02	-1.55	0.81	0.05	0.52

Ascelia Pharma AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.16 Mil.

Ascelia Pharma AB Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascelia Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

7ZA:Germany

Address

Hyllie Boulevard 34, Malmo, SWE, 215 32

Website

https://www.ascelia.com

Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.

Ascelia Pharma AB Headlines

No Headlines